We read with interest the comments of Gupta and Ram on our article entitled “Comparative Evaluation of Tacrolimus Versus Interferon Alpha-2b Eye Drops in the Treatment of Vernal Keratoconjunctivitis: A Randomized, Double-Masked Study.”1
We agree that patients with a history of herpes simplex keratitis and a history of contact lens wearing should be excluded from the study because of possible effects on results. In fact, we did not actually have any patient with a history of herpes simplex dendritic keratitis or a history of contact lens wearing, and we did not discuss about these in the article.
The dosage frequency of tacrolimus and interferon alpha-2b drops was 4 times a day for the first month and 2 times a day in the second month of administration.
As explained in the article, we had 40 patients (equal numbers in each group) with vernal keratoconjunctivitis, of which 31 patients (77.5%) were men. Of these, 31 male patients, 16 (51.6%) and 15 (48.4%) patients, were in the tacrolimus and interferon groups, respectively. There was no statistically significant difference between both groups regarding sex (P = 0.99). Thus, there was no actual discrepancy between the information presented in the abstract and in the text of the article.